Taken together, these results demonstrate that FOXO1 is a major player in T lymphocyte/HIV-1 interaction and that its pharmacological inhibition is a new potential clinical strategy to eradicate latent provirus reservoirs during HIV-1 infection. Here, FOXO1 is linked to HIV-1 infection.